Andeleeb Al Mobaraq-Dahy

Andeleeb Al Mobaraq-Dahy serves as the Vice President of Regulatory Affairs, bringing over 15 years of extensive experience in the field. She holds a master’s degree in Drug Innovation from the University of Utrecht and has a robust background as a pharmacist. Throughout her career, Andeleeb has held significant roles in the regulatory departments of major pharmaceutical companies including Astellas, Sanofi/Genzyme, and Novartis/Sandoz. She has been instrumental in leading multiple successful drug submissions to global health authorities such as the FDA, EMA, and PMDA. Andeleeb has developed comprehensive regulatory strategies for a broad range of therapeutic areas, covering both rare orphan diseases and prevalent common diseases. Additionally, she led the Innovative Medicines Initiative (IMI) project focused on optimizing R&D for advanced therapy medicinal products (ATMP), in partnership with other leading pharma and biotech companies. Her contributions have significantly impacted drug discovery and R&D in the pharmaceutical industry.